Want to take on Gilead in hep C, Merck? Try niche marketing, game theory expert says

In game theory, the so-called Judo strategy involves using the size and strength of opponents against them. And that's exactly what Yale Professor Barry Nalebuff thinks Merck ($MRK) should employ when it rolls out its next-gen hepatitis C regimen, setting up a battle with Gilead ($GILD) and AbbVie ($ABBV). "If you're small, a large player doesn't want to come down and swat you because it hurts them in the process. And so, the trick is to find a way to commit to being small," Nalebuff said, as quoted by Bernstein analyst Geoffrey Porges. "Is there some niche market that Merck can approach and thereby not make it worthwhile for Gilead to come after them?" More

Suggested Articles

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.

Novartis is rolling out head-to-head data for its MS drug in advance of an expected FDA approval next month, but competition will still be tough.

The FDA knocked Altaire Pharmaceuticals for falsified data and harebrained contraptions at its New York plant in a scathing warning letter.